Analysts Set Cullinan Therapeutics, Inc. (NASDAQ:CGEM) PT at $29.33

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $29.3333.

A number of analysts have weighed in on CGEM shares. Morgan Stanley restated an “overweight” rating and set a $30.00 price objective on shares of Cullinan Therapeutics in a research note on Thursday, January 8th. Citigroup began coverage on shares of Cullinan Therapeutics in a report on Tuesday, February 17th. They set a “buy” rating and a $33.00 price target on the stock. HC Wainwright boosted their price objective on shares of Cullinan Therapeutics from $26.00 to $27.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Zacks Research cut Cullinan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 19th. Finally, BTIG Research lifted their target price on Cullinan Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, November 24th.

Cullinan Therapeutics Price Performance

Shares of NASDAQ:CGEM opened at $14.36 on Thursday. The business has a fifty day moving average price of $11.50 and a 200-day moving average price of $9.31. The company has a market capitalization of $848.39 million, a PE ratio of -4.34 and a beta of -0.09. Cullinan Therapeutics has a 1-year low of $5.68 and a 1-year high of $14.56.

Insider Buying and Selling

In other news, CFO Mary Kay Fenton sold 4,398 shares of the firm’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $13.62, for a total transaction of $59,900.76. Following the sale, the chief financial officer owned 126,380 shares of the company’s stock, valued at $1,721,295.60. This trade represents a 3.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jennifer Michaelson sold 3,601 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $14.47, for a total transaction of $52,106.47. Following the completion of the sale, the insider owned 176,624 shares of the company’s stock, valued at $2,555,749.28. This represents a 2.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 98,132 shares of company stock worth $1,269,632 in the last three months. 7.16% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dynamic Technology Lab Private Ltd bought a new stake in Cullinan Therapeutics in the 1st quarter worth approximately $163,000. Jane Street Group LLC boosted its stake in shares of Cullinan Therapeutics by 145.9% in the 1st quarter. Jane Street Group LLC now owns 34,396 shares of the company’s stock worth $260,000 after buying an additional 109,413 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Cullinan Therapeutics in the first quarter worth $618,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Cullinan Therapeutics in the second quarter worth $84,000. Finally, Corton Capital Inc. increased its position in Cullinan Therapeutics by 28.9% during the second quarter. Corton Capital Inc. now owns 21,712 shares of the company’s stock valued at $163,000 after acquiring an additional 4,870 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Key Headlines Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Neutral Sentiment: Recent short-interest data for CGEM appears unreliable (reports show 0 shares and NaN change), so there’s no clear evidence of rising short interest to explain price moves — treat that data as a likely reporting glitch.
• Neutral Sentiment: Broader market weakness (e.g., a sharp pullback in Bitcoin this month) can contribute to risk-off flows in small-cap and biotech stocks, but this is an indirect factor. Bitcoin article
• Negative Sentiment: Multiple insiders sold shares on Feb. 24 — combined ~27,051 shares (~$390.6k at ~ $14.47 average). CEO Nadim Ahmed sold 13,515 shares (≈$195.6k), reducing his stake by ~3.34%. These sizable, contemporaneous sales by the CEO and other executives can be perceived negatively by the market as signal of insider profit-taking or reduced conviction. SEC filings: Ahmed filing, Sumer filing, Jones filing, Michaelson filings

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.